How Invex’s Exenatide Breakthrough Could Transform Alzheimer’s Treatment

• FY25 net loss narrowed to $476,868 from $1.64 million in FY24
• R&D expenses dropped sharply following Phase III trial closure
• New collaboration with Tessara Therapeutics yields encouraging Alzheimer’s disease model results
• Strong cash position of $5.38 million maintained
• UK subsidiary deregistration underway to reduce overheads

Financial Performance and Cost Restructuring

Invex Therapeutics Ltd has reported a marked improvement in its financial results for the year ended 30 June 2025, posting a net loss of $476,868 compared to a loss of $1.64 million in the prior year. This significant reduction is largely attributed to the closure of the IIH EVOLVE Phase III clinical trial, which led to a steep decline in research and development expenditure from over $2 million to just $204,495. Corporate and administrative costs were also trimmed, reflecting a strategic cost restructuring as the company pivots back to pre-clinical development.

Advancing Exenatide in Neurodegenerative Disease

Central to Invex’s ongoing strategy is the repurposing of Exenatide, a GLP-1 receptor agonist, for neurological conditions linked to raised intracranial pressure and neurodegeneration. In FY25, Invex deepened its collaboration with Australian biotech Tessara Therapeutics, leveraging Tessara’s proprietary ADBrain™ 3D human neural micro-tissue model to explore Exenatide’s therapeutic potential in Alzheimer’s Disease. Initial pre-clinical results released in December 2024 demonstrated that Exenatide significantly improved cell viability under oxidative stress and ferroptosis conditions, marking the first evidence of a GLP-1 receptor agonist’s neuroprotective effect in a human Alzheimer’s model.

Expanding Research and Intellectual Property Prospects

Building on these promising findings, Invex expanded the Tessara collaboration in early 2025 to include detailed analyses of Exenatide’s impact on Alzheimer’s biomarkers, neural network morphology, and gene/protein expression profiles. These studies aim to generate new intellectual property that complements Invex’s existing patents related to intracranial pressure disorders. Results from this expanded research program are anticipated in the latter half of 2025, potentially opening new avenues for clinical development and commercialisation.

Corporate Developments and Market Position

Invex maintains a robust cash position of $5.38 million as of June 30, 2025, supported by a £113,967 UK R&D tax rebate received in January 2025. The company is in the process of deregistering its UK subsidiary, established for the Phase III trial, to further reduce annual overheads by approximately $100,000. Invex also continues to evaluate additional neurological and non-neurological assets to potentially broaden its pipeline, though no binding agreements have been made to date.

Leadership and Governance

The company’s leadership team, including Non-Executive Chairman David McAuliffe and Executive Director Dr Thomas Duthy, remains focused on delivering shareholder value through disciplined financial management and strategic R&D investments. The Board’s remuneration policies reflect a balance between competitive compensation and alignment with long-term company objectives, with no dividends proposed for FY25.

Bottom Line?

Invex’s FY25 results and promising Alzheimer’s pre-clinical data set the stage for a pivotal year ahead as it seeks to translate scientific advances into clinical and commercial milestones.

Questions in the middle?

• Will the upcoming detailed pre-clinical data from Tessara validate Exenatide’s potential in Alzheimer’s treatment?
• How will the deregistration of the UK subsidiary impact Invex’s operational efficiency and cost structure?
• What new assets or partnerships might Invex pursue to expand its neurological pipeline?